SER-270 / POZ-VMAT2i
for Tardive Dyskinesia (TD)
POZ enables a VMAT2 inhibitor-based LAI product candidate optimized for one week PK profile in movement disorders Tardive Dyskinesia & Huntington’s Chorea
Targeting Non-Compliant Psychiatric Patients
-
TPP: Long acting injectable vs. daily orals
-
PK Profile: near zero-order, providing constant drug levels without interruption (elimination of large peak-to-trough ratio)
-
Setting: Many patients on LAI antipsychotics may benefit from our TPP where a weekly injection could reduce burden and improve adherence.
Tardive dyskinesia (TD) is a chronic drug-induced movement disorder characterized by involuntary movements in the body or face
25.3%
Prevalence of TD among patients treated with any antipsychotic medication
800K
people in the US are currently living with Tardive dyskinesia
Only 50K
patients are currently being treated with VMAT2 inhibitors
VMAT2i’s
are the only approved drug class for Tardive dyskinesia
SER-270
(POZ-VMAT2 inhibitor)
VMAT2 inhibitor-based long-acting injectable (LAI) in movement disorders Tardive Dyskinesia & Huntington’s Chorea